Treatment of psoriasis in end-stage renal disease patients is associated with decreased mortality: A retrospective cohort study

Schwade, Mark; Tien, Lillie; Waller, Jennifer L.; Davis, Loretta S.; Baer, Stephanie L.; Mohammed, Azeem; Young, Lufei; Kheda, Mufaddal; Bollag, Wendy B.

doi:10.1016/j.amjms.2021.03.009

Cited by 11 publications

(11 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comorbidities could influence the treatment strategy (14). Figure 2 lists selected therapeutics for adult systemic psoriasis with comorbidities (74)(75)(76)(77). Treatment should be tailored to meet the needs of patients (Figure 2).…”

Section: Therapy For Psoriasismentioning

confidence: 99%

Cutaneous and Systemic Psoriasis: Classifications and Classification for the Distinction

Yan

Chen

et al. 2021

Front. Med.

View full text Add to dashboard Cite

Psoriasis is a chronic multisystem inflammatory disease that affects ~0.1–1.5% of the world population. The classic cutaneous manifestation of psoriasis is scaly erythematous plaques, limited or widely distributed. Moreover, psoriasis could be associated with comorbidities like psoriatic arthritis, metabolic syndrome, diabetes, cardiovascular disease, nephropathy, bowel disease, and brain diseases. In this review, we suggest that psoriasis should be classified as cutaneous psoriasis or systemic psoriasis and propose the classification for distinction. This would help to better understand and manage psoriasis.

show abstract

Section: Therapy For Psoriasismentioning

confidence: 99%

Cutaneous and Systemic Psoriasis: Classifications and Classification for the Distinction

Yan

Chen

et al. 2021

Front. Med.

View full text Add to dashboard Cite

show abstract

“…However, it is important to carefully weigh the risks and benefits of transplantation, considering factors such as the patient's overall health status, comorbidities, and eligibility for transplantation, in collaboration with a multidisciplinary medical team. Another retrospective cohort study involving 8911 patients emphasized the heightened risk of infections in individuals with both psoriasis and ESRD, a ributed not only to the underlying renal dysfunction but also to the altered function of the epidermal barrier and the presence of permanent venous accesses associated with hemodialysis [25]. Furthermore, this study highlighted the potential benefits of appropriate therapeutic management of psoriasis in this population.…”

Section: Discussionmentioning

confidence: 89%

Section: Discussionmentioning

confidence: 99%

“…The effective control of psoriasis has been associated with a reduction in the risk of infections and an improvement in overall survival among patients with ESRD. This underscores the importance of the proactive management of psoriasis in patients undergoing hemodialysis to mitigate the risk of infections and enhance long-term outcomes [25]. Currently, the majority of available data on therapy with biologic drugs in this specific setting primarily stem from case reports and case series focusing on the treatment of individuals with psoriasis undergoing hemodialysis (HD).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Successful Treatment with Bimekizumab of a Psoriatic Patient Undergoing Hemodialysis: A Case Report and Review of the Literature

Bernardini,

Ambrosio,

Tolino

et al. 2024

JCM

View full text Add to dashboard Cite

Background/Objectives: Treating psoriasis patients requires the consideration of potential underlying complications like latent viral infections and chronic kidney disease, which may influence therapy selection. Case presentation: A patient with end-stage kidney disease (ESKD) undergoing hemodialysis (HD) was successfully treated with bimekizumab, an IgG1 humanized monoclonal antibody inhibiting interleukin (IL)-17A and IL-17F. This case appears to be the first documented instance of effective anti-IL-17A/IL-17F antibody treatment in a psoriasis patient undergoing HD, with a sustained positive response for eight months. Discussion: Studies indicate the comparable pharmacokinetics, efficacy, and safety of certain psoriasis drugs in patients with chronic kidney disease (CKD) and those with normal renal function. The positive clinical outcome observed following treatment with bimekizumab aligns with the existing literature on this topic. However, further studies are needed to objectively evaluate the pharmacokinetics, efficacy, and safety of this drug in this specific setting. Conclusions: This documented case represents the first known use of bimekizumab to treat psoriasis in patients undergoing dialysis, suggesting its potential effectiveness and safety in this population.

show abstract

“…Nail alterations occur among 4.2% and 69% of all psoriasis patients. Psoriasis sufferers are said to be more susceptible to acquiring other serious clinical conditions like cardiovascular disease and other noncommunicable diseases (NCDs) [15][16][17][18]. Psoriasis is extremely taxing on the body, the mind, and society.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of Dialysis in Psoriasis: A Short Review

Pandey¹,

Kumar²

2022

Cureus

View full text Add to dashboard Cite

Psoriasis is a chronic, incurable condition with an erratic course of symptoms and triggers by nature. Psoriasis patients need medical attention that extends beyond only treating skin conditions and joint issues. Because psoriasis is so complex, treating it with medication alone does not work well; comprehensive, whole-person treatment is required. Screening for concomitant diseases including hypertension, dyslipidemia, diabetes mellitus, cardiovascular issues, and their adverse effects like myocardial infarction and stroke is a part of treating psoriasis. Regular screening for these linked illnesses should be done. Essential elements of psoriasis care include co-medication to avoid drug interactions or drug-induced psoriasis, as well as the identification and management of trigger factors. The lack of widely used and established diagnostic criteria restricts these studies. Essential elements of psoriasis management include routine screening for these associated disorders, co-medication to avoid drug interactions or psoriasis caused by drugs, as well as the identification of trigger factors and their management. This short review highlights the effectiveness of dialysis in people with psoriasis and the fact that the benefit is more pronounced with peritoneal dialysis than with hemodialysis.

show abstract

Treatment of psoriasis in end-stage renal disease patients is associated with decreased mortality: A retrospective cohort study

Cited by 11 publications

References 54 publications

Cutaneous and Systemic Psoriasis: Classifications and Classification for the Distinction

Cutaneous and Systemic Psoriasis: Classifications and Classification for the Distinction

Successful Treatment with Bimekizumab of a Psoriatic Patient Undergoing Hemodialysis: A Case Report and Review of the Literature

Effectiveness of Dialysis in Psoriasis: A Short Review

Contact Info

Product

Resources

About